Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy

W. Douglas Biggara,*, Andrew Skalskyb and Craig M. McDonaldc

aUniversity of Toronto, 15583 22nd Side Road, Georgetown, Ontario, Canada
bUniversity of California San Diego, Rady Children’s Hospital San Diego, MC, San Diego, CA, USA
cUniversity of California Davis Health, Departments of Physical Medicine & Rehabilitation and Pediatrics, Lawrence J. Ellison Ambulatory Care Center, Sacramento, CA, USA

Pre-press 14 June 2022

Abstract. Deflazacort and prednisone/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival. Both have been used off-label for many years (choice dependent on patient preference, cost, and geographic location) before FDA approval of deflazacort for DMD in 2017. In this review, we compare deflazacort and prednisone/prednisolone in terms of their key pharmacological features, relative efficacy, and safety profiles in patients with DMD. Differentiating features include lipid solubility, pharmacokinetics, changes in gene expression profiles, affinity for the mineralocorticoid receptor, and impact on glucose metabolism. Evidence from randomized clinical trials, prospective studies, meta-analyses, and post-hoc analyses suggests that patients receiving deflazacort experience similar or slower rates of functional decline compared with those receiving prednisone/prednisolone. Regarding side effects, weight gain and behavior side effects appear to be greater with prednisone/prednisolone than with deflazacort, whereas bone health, growth parameters, and cataracts appear worse with deflazacort.

Keywords: Deflazacort, duchenne muscular dystrophy, glucocorticoids, prednisone, prednisolone

INTRODUCTION

Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, occurs in 15.9 per 100,000 live male births in the US and 19.5 per 100,000 live male births in the UK [1–3]. This lethal, X-linked neuromuscular disorder is caused by a mutation in the dystrophin gene (DMD) [4]. Dystrophin provides structural stability to skeletal muscles. The absence of normal dystrophin makes muscles more susceptible to contractile damage [5].

The typical DMD phenotype includes significant progressive skeletal muscle weakness in early childhood with loss of ambulation (LoA) typically by age 5

[Correspondence to: Douglas Biggar, University of Toronto, 15583 22nd Side Road, Georgetown, Ontario, L7G 4S8, Canada. Tel.: +416 268 6791D; E-mail: dbiggard@gmail.com.]

ISSN 2214-3599 © 2022 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).
years and older and the label was expanded in June 2019 to include patients aged 2 to 5 years [8]. It was approved in other countries for decades prior to this and used off-label in the US among those who were able to gain access to foreign supplies [9]. Prednisone/prednisolone continues to be alternatively prescribed off-label for the treatment of DMD in the US.

COMPARING DEFLAZACORT AND PREDNISONE/PREDNISOLONE IN DMD

Chemical structure

Prednisone, prednisolone and deflazacort are synthetic glucocorticoids, with deflazacort being an oxazoline derivative of prednisolone [10]. All three compounds are heterocyclic: prednisone and prednisolone having four rings and deflazacort having five rings (Fig. 1) [10]. The structural characteristics of deflazacort may explain some of its differing pharmacological activities from prednisone/prednisolone, including its lack of sodium-retaining activity and lower interference with carbohydrate metabolism in comparison with classic corticosteroids [10].

Mechanisms of action

The exact mechanisms of action of deflazacort and prednisone/prednisolone in DMD have not yet been fully elucidated but are clearly multifaceted, with both drugs affecting multiple gene expression pathways. One study evaluated mRNA transcripts from muscle biopsies from nine boys with DMD, collected before and after 3 months of deflazacort treatment, in comparison with those of eight healthy boys [11]. In dystrophic muscle, the expression of genes important for myogenesis, muscle regeneration and muscle maturation was increased towards normal ranges by deflazacort treatment, while expression of several genes with roles in inflammation was reduced towards normal ranges [11]. In a second study that compared gene expression in whole blood from 14 corticosteroid-treated children and adolescents with DMD with 20 who were corticosteroid-naïve, treatment with corticosteroids was found to upregulate genes associated with primary and secondary granules in neutrophils, iron trafficking, and chondroitin sulfate synthesis [12]. When comparing gene expression in deflazacort- and prednisone-treated individuals, there were fewer expression changes overall with deflazacort versus prednisone. Differences between the treatments centered on genes involved in adipose metabolism, potentially suggesting mechanisms by which corticosteroid-related weight gain, more typically associated with prednisone/prednisolone than with deflazacort, may be orchestrated [12].

Pharmacokinetics and pharmacodynamics

Both deflazacort and prednisone are prodrugs. Deflazacort is deacetylated by plasma esterases in vivo to the active form, deflazacort-21-hydroxide [13]. Prednisone is metabolized in the liver by 11ß-hydroxysteroid dehydrogenase to the active form, prednisolone [14].
Deflazacort exhibits linear, dose-proportional pharmacokinetics. The absolute oral bioavailability of deflazacort is 68%, and less than 40% was bound to plasma proteins after administration in healthy volunteers [13]. After a single 30 mg dose of deflazacort, maximum plasma concentrations of deflazacort-21-hydroxide were 121 μg/L (oral) and 652 μg/L (intravenous) [13]. The pharmacokinetics of prednisolone and prednisone are dose-dependent due to nonlinear protein binding. Protein binding of prednisolone decreases nonlinearly from 95% to about 60 to 70%, while the plasma concentration increases from 200 μg/L to 800 μg/L when protein binding reaches a plateau, observed with doses above approximately 20 mg [15].

The half-life of deflazacort after oral and intravenous administrations is 1.8 hours and 1.5 hours, respectively [13], whereas the half-life of prednisolone is approximately 3 hours when administered via either route.

The dosing ratio of deflazacort to prednisone/prednisolone is nearly 85%; thus, 6 mg of deflazacort is roughly equivalent to 5 mg of prednisone/prednisolone [13, 16].

Key differentiating features

Deflazacort has lower lipid solubility than prednisolone [17]. It has no affinity for transcortin, binding instead to plasma protein and blood cells. Deflazacort crosses the blood-brain barrier more poorly than prednisone/prednisolone [17].

The lower lipid solubility may explain the lower crossing of the blood brain barrier with deflazacort relative to prednisone and the resultant greater behavioral side effects observed with prednisone/prednisolone [18]. The greater aqueous distribution of deflazacort may also account for the greater frequency of cataract formation with this drug versus prednisone/prednisolone due to the lens of the eye being adjacent to a fluid filled structure [19].

Glucocorticoids alter glucose metabolism, inducing a diabetes-like state in some individuals [20]. The rates of hyperglycemia and diabetes induced by glucocorticoid therapy vary depending on the population studied, but have been estimated at 32% and 19%, respectively, in patients without prior diabetes [21]. Deflazacort has less effect on glucose metabolism than prednisone/prednisolone, even in those with a family history of diabetes [10, 13]. Long-term administration of deflazacort at doses up to 50 mg per day has been shown to have no effect on glucose metabolism [13].

Deflazacort has little to no affinity for the human mineralocorticoid receptor, and the active metabolite, deflazacort-21-hydroxide, shows low transactivation [22]. This was shown in a binding assay, in which deflazacort showed no transactivation; the potencies of deflazacort and its active metabolite were not detectable [22]. By contrast, the mineralocorticoid activity of prednisone/prednisolone is about half that of natural glucocorticoids and their sodium retaining potency is about 80% that of cortisol [10]. Deflazacort is believed to have a lower impact on calcium metabolism than other synthetic glucocorticoids, with a resulting lower risk osteoporosis/osteopenia in the first decade of treatment [10, 23, 24].

GLUCOCORTICOIDS AS STANDARD OF CARE IN DMD

Guideline recommendations and meta-analysis

The 2016 update of the American Academy of Neurology guidelines on corticosteroid treatment in DMD [25] and a Cochrane systematic review published in 2016 [10] conclude that corticosteroids improve strength, timed motor function and pulmonary function, delay LoA and onset of cardiomyopathy, reduce need for scoliosis surgery, and increase survival [25].

Recent studies of corticosteroid use in DMD

Several new studies, published since the guidelines mentioned above, shed additional light on the impact of corticosteroids in DMD. One randomized placebo-controlled trial of 196 patients was included in the Cochrane review in abstract form only but has since been published in full [26]. Patients were aged 5 to 15 years, with onset of weakness at an age below 5 years, and were randomized to deflazacort (0.9 or 1.2 mg/kg/d), prednisone/prednisolone (0.75 mg/kg/d) or placebo. At 12 weeks, compared with the placebo group, patients who received prednisone/prednisolone (p = 0.0002) or deflazacort at 0.9 mg/kg/d (p = 0.017) or 1.2 mg/kg/d (p = 0.0003) had significantly improved muscle strength [26].

Long-term observational data of value have emerged in recent years, notably from the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study. An analysis from this prospective dataset included a cohort
of 440 patients with DMD aged 2 to 28 years from 20 centers in nine countries, with follow-up for up to 10 years [27]. In order to assess the impact of glucocorticoid therapy, no glucocorticoid treatment or cumulative treatment of less than 1 month was compared with glucocorticoid treatment for 1 year or more. Glucocorticoid treatment protocols included daily dosing and other less frequent schedules, most commonly alternate-day dosing. Outcomes in terms of nine disease-related and clinically meaningful mobility and upper limb milestones were assessed. Time to all disease progression milestones was significantly longer among patients treated with glucocorticoids (prednisone, prednisolone or deflazacort) for at least 1 year, compared with those treated for less than 1 month or never treated \((p<0.0001)\). The median age at loss of mobility milestones and upper limb milestones was increased by 2.1 to 4.4 years and 2.8 to 8.0 years, respectively, among patients treated with glucocorticoids for at least 1 year compared with treatment-naive patients or those treated for less than 1 month. Median age at LoA was 10.0 years for non-corticosteroid treated patients and 13.4 years for patients receiving corticosteroids \((p<0.0001)\). All-cause mortality over the timeframe of the study was lower with glucocorticoid treatment. A total of 28 (9%) deaths occurred in 311 patients treated with glucocorticoids for 1 year or longer compared with 11 (19%) deaths in 58 patients with no history of glucocorticoid use (odds ratio 0.47, 95% CI, 0.22–1.00; \(p=0.0501\)). Glucocorticoids also affected the annual rate of decline in forced vital capacity (FVC) predicted in DMD prior to the age of 10, resulting in a higher peak absolute FVC and a prolonged time to an FVC of 1 liter – a critical late milestone linked to a 4-fold increased risk of death in patients with DMD [27, 28].

The TREAT-NMD global DMD database combines clinical data from patients with DMD from 31 countries [29]. A cross-sectional study analyzed TREAT-NMD data from 5345 patients with DMD to investigate the impact of corticosteroids on major clinical outcomes [30]. Almost half (49.7%) of the study population were concomitantly using corticosteroids, 37.7% had never used corticosteroids and 9.8% reported past use (use for the remaining 2.8% was unknown). Median age at LoA was 10 years for non-corticosteroid treated patients and 13 years for patients receiving corticosteroids \((p=0.0001)\), almost identical to that found in the prospective CINRG database. Corticosteroid-treated patients were less likely to need scoliosis surgery \((p<0.001)\) or ventilatory support \((p<0.001)\) and there was a mild cardioprotective effect of corticosteroids in the patient population aged 20 years and older \((p=0.0035)\). Respiratory and cardiac function were also studied in an Italian cohort of patients with DMD (327 patients with spirometric data and 374 with echocardiographic data; mean follow-up of 4.5 years and 2.6 years, respectively) [31]. Glucocorticoid use significantly improved respiratory function \((+14.5\% \text{ FVC}; p<0.001)\), but not cardiac function.

A prospective observational study from centers in Italy, the UK and USA followed 153 boys with DMD aged 3–6 years at baseline, for a minimum of 1 year and documented functional changes using the North Star Ambulatory Assessment (NSAA) scale [32]. NSAA scores progressively increased with age and multilinear regression analysis showed that use of corticosteroids significantly contributed to this change \((p<0.001)\). At each age point, boys receiving corticosteroids had higher NSAA scores than corticosteroid-naïve patients \((p<0.001)\).

A US population-based study of 477 patients identified by the Muscular Dystrophy Surveillance Tracking and Research Network (MDSTARnet) stratified glucocorticoid treatment duration into short (0.25–3 years), long (>3 years) and no treatment [33]. Patients who received long-term treatment lost ambulation 2 years later, and had an 82% lower annual risk of losing ambulation, than untreated patients up to age 11. Unexpectedly, patients who received short-term treatment lost ambulation 0.8 years earlier and had a 77% higher annual risk of losing ambulation than those who were untreated.

Intermittent, rather than daily, corticosteroid treatment is a regimen used by some patients, and a recent UK retrospective longitudinal study suggests similar outcomes with these two regimens [34]. The study included 270 patients (mean age, 6.2 ± 2.3 years), 182 on intermittent steroids, 66 on daily steroids and 22 steroid-naïve patients [34]. Yearly FVC% predicted declined similarly from 9 years of age for patients receiving daily or intermittent corticosteroids (5.9% and 6.9% per year, respectively; \(p=0.27\)). Those receiving daily corticosteroids declined from a higher FVC% predicted than the intermittent corticosteroid group \((p<0.05)\) and both declined to an FVC% predicted of below 50% and required non-invasive ventilation at a similar age, more than two years later than patients in the steroid-naïve group. Age at onset of cardiomyopathy was significantly later for corticosteroid-treated
patients compared with steroid-naïve patients, irrespective of the regimen (16.6 years vs 13.9 years; p < 0.05).

A small, single-center retrospective analysis compared 12 patients receiving daily corticosteroids with 12 patients (matched for age, BMI, and treatment duration) receiving weekend higher dose pulse corticosteroids [35, 36]. Cardiac and functional measurements did not differ between the two groups but the pulse weekend group showed improved metabolic and bone health measures compared with the daily steroid group (whole body fat mass, 36.3% vs 50.4% [p = 0.002]; total body bone mineral density Z-score, −1.20 vs −2.92 [p < 0.001]; glucose, 105 mg/dL vs 127 mg/dL [p = 0.005]).

Adverse events associated with glucocorticoids in DMD

Side-effects associated with long-term corticosteroid use are well documented. Particular concerns include weight gain, effects on linear growth, behavioral effects, pubertal delay and increased risk of vertebral fractures [37–39]. Other common adverse events (AEs) include Cushingoid features, hirsutism, acne, increased insulin resistance, and frank glucose intolerance [38]. Long-term administration of corticosteroids may lead to suppression of the hypothalamic-pituitary-adrenal (HPA) axis such that the adrenal glands no longer produce endogenous cortisol [40]. If corticosteroids are stopped abruptly, adrenal insufficiency can result which may progress to adrenal crisis [37]. Some AEs associated with glucocorticoid therapy can be mitigated by dose reduction or alternative dosing regimens, if warranted (Table 1), although the potential impact of reducing dose on treatment efficacy should be considered [37].

Assessment of glucocorticoid efficacy and non-physical AEs by patients and their caregivers may be useful to ascertain maximum benefit of therapy and to determine whether these AEs change over time. To this end, the 23-item SIDECORT (SIDE Effect of glucoCORTicoids) questionnaire was developed. It was designed to address perceptions by patients and their parents with regard to cognition, emotional functioning, and behavior [41]. SIDECORT can be regarded as having four components: general information, potential benefit from steroid therapy, putative AEs from steroid therapy, and overall impression regarding treatment [41]. In the study reporting the development of the SIDECORT questionnaire, a cohort of 86 patients and 125 of their parents completed the questionnaire. Results regarding treatment duration and AEs showed that parents reported more negative and significant correlations between treatment duration and getting upset easily, distraction, restlessness, and other psychosocial parameters, but no correlation with physical side effects. In contrast, patients reported positive correlations between treatment duration with physical side effects, especially with being hungry often and having Cushingoid features [41].

| Adverse event                          | Monitoring                           | Management                                              |
|----------------------------------------|--------------------------------------|---------------------------------------------------------|
| Cushingoid features, excessive weight gain | Monitor food intake at every clinic visit, forewarn about increased appetite | Proactive dietary management; select alternative regimen |
| Hirsutism                              | Forewarn                             | Usually none required                                    |
| Acne, warts                            | More common in teens                 | Ancillary treatment measures                             |
| Tinea corporis                         | More common in teens                 | Systemic or topical antifungal                          |
| Delayed puberty                        | Monitor Tanner stage                 | Consider endocrine assessment                            |
| Adrenal suppression                    | Patient should carry a steroid alert card; do not stop treatment abruptly | Stress-dose with hydrocortisone or methylprednisolone before surgery or with major illness; endocrine consult recommended |
| Bone demineralization/increased fracture risk and bone pain | Annual dual-energy x-ray absorptiometry and monitoring of blood vitamin D3 levels; supplement calcium and vitamin D3 if warranted | Vitamin D3 measurements may vary with different laboratories. Give 1000–2000 IU once daily. If Vitamin D levels are low, supplement and monitor. Seek a bone specialist consultation for prevention and/or treatment of fragility fractures and/or bone pain |
| Glucose intolerance                    | Urine dipstick at clinic visits; monitor for polyuria or polydipsia | Check for glucose tolerance; seek endocrine consult |

Abbreviation: IU = International Unit. Adapted from Birnkrant 2018 [37] and the PJ Nicholoff Steroid Protocol [69].
Many individuals with DMD have been treated with glucocorticoids for more than 10 years; however, at the time of writing, we are not aware of any data on the prevalence and management of adverse effects in these young men. This is an important gap in our knowledge, particularly with regard to bone health, bowel and bladder function, nutrition, cataracts, and psychosocial wellbeing.

**Direct comparisons of efficacy and safety – randomized trials**

Table 2 summarizes the key studies providing data on head-to-head comparisons of deflazacort and prednisone/prednisolone. Griggs et al describe the largest randomized head-to-head trial of deflazacort and prednisone in DMD yet performed [26]. The multicenter trial enrolled 196 patients aged 5 to 15 years, with onset of weakness at an age of less than 5 years. Patients were randomized to deflazacort (0.9 or 1.2 mg/kg/d), prednisone (0.75 mg/kg/d) or placebo. At 12 weeks, the active treatment groups had small but significant improvements in average muscle strength compared with placebo, but there were no significant differences between deflazacort and prednisone at this time point (least squares [LS] mean change versus placebo for: deflazacort 0.9 mg/kg/d, 0.25 vs 20.1, \( p = 0.017, 95\% \) confidence interval [CI], 0.04–0.46; deflazacort 1.2 mg/kg/d, 0.36 vs 20.1, \( p = 0.0003, 95\% \) CI, 0.14–0.57; prednisone 0.75 mg/kg/d, 0.37 vs 20.1, \( p = 0.0002, 95\% \) CI, 0.15–0.59). After a further 40 weeks’ treatment (i.e. at week 52), muscle strength continued to improve with deflazacort at the usual starting dose of 0.9 mg/kg/d, but worsened with prednisone, with the differences from week 15 to 52 between deflazacort 0.9 mg/kg and prednisone being significant (LS mean treatment difference, 0.29, \( p = 0.044, 95\% \) CI, 0.08–0.49); however, the differences over this period between deflazacort (1.2 mg/kg/d) and prednisone were not significant, and overall differences between deflazacort and prednisone in change from baseline to week 52 were not significant. At week 12, there were significant increases in weight and BMI, with prednisone versus placebo (weight: LS mean 3.23 vs 1.23, \( p = 0.0459, 95\% \) CI, 0.03–3.97; BMI: LS means 1.47 vs 0.16, \( p = 0.0041, 95\% \) CI, 0.35–2.29); in contrast, there were no significant differences between the deflazacort groups and placebo. At 52 weeks, the deflazacort groups showed significantly smaller increases in weight and BMI than participants originally randomized to prednisone. There was no significant difference between the number of participants with at least one treatment-emergent AE (TEAE) in either deflazacort group compared with the prednisone group. The two most commonly reported TEAEs were Cushingoid appearance and erythema, which were more common in the prednisone group than in the deflazacort 0.9 mg/kg/d group (\( p = 0.0385 \) for Cushingoid appearance and \( p = 0.0071 \) for erythema), but comparable in the deflazacort 1.2 mg/kg/d group (\( p = 0.3198 \) and \( p = 0.7277 \), respectively).

In a small single-blind study in Iran, 34 patients, aged 3 to 10 years, were randomized to deflazacort (0.9 mg/kg daily) or prednisone (0.75 mg/kg daily) for 18 months [42]. Motor function was assessed using an index that scored ability to get up from the ground, walking on flat ground for 10 meters and going up four steps, in which lower scores indicated better ability to perform the task. At 1 year, mean motor function score had decreased by 11.19 (95% CI, –19.8––2.5) in patients receiving deflazacort and increased by 5.20 (95% CI, –9.9–20.3) in patients receiving prednisone (\( p = 0.001 \)). However, there was no difference between groups by the end of the study (mean change from baseline, –4.52 [95% CI, –19.8–10.7] for deflazacort and +14.79 [95% CI, –9.7–39.2] for prednisone; \( p = 0.128 \)). Weight gain was greater at 1 year and at 18 months in the prednisone group compared with the deflazacort group (increase in weight for prednisone vs deflazacort was 21.65% vs 12.95% at 1 year [\( p = 0.001 \)] and 32.04% vs 21.67% at 18 months [\( p = 0.046 \)]).

Another very small study, conducted in Italy, included only 18 patients aged 5 to 14 years [43]. This was a double-blind, randomized, multicenter equivalence study in which patients received deflazacort 0.9 mg/kg/d (\( n = 8 \)) or prednisone 0.75 mg/kg/d (\( n = 11 \)) for 1 year. Comparisons were made with another group of untreated patients, serving as a natural history cohort. Deflazacort and prednisone were equally effective in improving motor function and functional performance at 1 year. At 9 months, the average weight increase vs baseline was 5% in the deflazacort group and 18% in the prednisone group (\( p < 0.005 \)).

Two of the three randomized clinical trials showed differences in selected motor skills favoring deflazacort over prednisone at 12 months, and the largest of these studies also demonstrated an improvement in strength; and two of the three trials showed that participants taking deflazacort experienced less weight gain than those taking prednisone.
### Table 2

Studies comparing deflazacort and prednisone/prednisolone

| Reference | N     | Age (years) | Comparators                                      | Duration | Outcomes                                      |
|-----------|-------|-------------|--------------------------------------------------|----------|-----------------------------------------------|
| RCTs      |       |             |                                                  |          |                                               |
| Griggs 2016 [26] | 196   | 5–15        | DFZ 0.9 mg/kg/d \(n = 51\) DFZ 1.2 mg/kg/d \(n = 49\) PRED 0.75 mg/kg/d \(n = 46\) Placebo \(n = 50\) | 52 weeks | Muscle strength Weight/BMI Other TEAEs       |
| Karimzadeh 2012 [42] | 34    | 3–10        | DFZ 0.9 mg/kg/d \(n = 17\) PRED 0.75 mg/kg/d \(n = 17\) | 18 months | Motor function Weight gain                   |
| Bonifati 2000 [43] | 18    | 5–14        | DFZ 0.9 mg/kg/d \(n = 9\) PRED 0.75 mg/kg/d \(n = 9\) | 12 months | Muscle strength and function (Medical Research Council score) Mean weight increase |
|          |       |             |                                                  |          |                                               |
|          |       |             |                                                  |          |                                               |
| Observational |      |             |                                                  |          |                                               |
| Bello 2015 [7] | 340   | 2–28        | DFZ (daily, \(n = 80^*\)) PRED (daily, \(n = 94^*\)) (Various regimens) | Mean follow-up 3.8 ± 1.8 years | LoA Weight gain TEAEs |
| McDonald 2018 [27] | 440   | 2–28        | DFZ daily \(n = 107\) PRED daily \(n = 40\) PRED intermittent \(n = 63\) (Various regimens) | Up to 10 years | LoA Loss of supine to stand Loss of hand to mouth function Other disease milestones and timed function tests |
| Goemans 2020 [45] | 316   | 4–19        | DFZ \(n = 202\) PRED \(n = 114\) (Regimens not reported) | 900 patient-years | Loss of ability to rise from supine |
| Joseph 2019 [24] | 832   | Median 6.9 at baseline | DFZ daily \(n = 40\) DFZ intermittent \(n = 12\) PRED daily \(n = 151\) PRED intermittent \(n = 130\) (Various regimens) | Mean follow-up 4.0 years | Fracture incidence |
| Lamb 2016 [23] | 324   | 2–12        | DFZ\(^{†}\) \(n = 56\) PRED\(^{†}\) \(n = 136\) (Various regimens) | Up to 30 years (retrospective study) | Height Weight/BMI |
| Rice 2018 [50] | 514   | Mean 12.5 at last visit | DFZ 0.9 mg/kg/d \(n = 403\) PRED 0.75 mg/kg/d \(n = 111\) (Daily or intermittent, titrated as required) | 6 years (retrospective study) | Cataract formation |

**Post-hoc analyses of placebo arms of industry-sponsored trials**

| Shieh 2018 [51] | 114   | Mean 9.0 at baseline | DFZ 0.695 mg/kg/day (mean; \(n = 53\)) PRED 0.515 mg/kg/day (mean; \(n = 61\)) | 48 weeks | Physical functioning Delay in LoA |
| McDonald 2019 [52] | 231   | Mean at baseline: tadalafil DMD trial placebo arm, 9.5 years; ACT DMD placebo arm, 9.0 years | DFZ\(^{‡}\) \(n = 111\) PRED\(^{‡}\) \(n = 120\) | 48 weeks | 6-minute walking test |
| Shieh 2021 [53] | 146   | Mean at baseline: ataluren phase 2b placebo arm, 9.1 years (DFZ) and 8.3 years (PRED); ACT DMD placebo arm, 9.2 years (DFZ) and 8.8 years (PRED) | DFZ\(^{‡}\) \(n = 70\) PRED\(^{‡}\) \(n = 84\) | 48 weeks | 6-minute walking test 10 m walk/run 4-stair climb 4-stair descend Adverse events |

\(^*\)Patient numbers given for daily dosing regimen; various intermittent deflazacort and prednisone regimens were also observed. \(^\dagger\) At least daily. \(^\ddagger\) Regimen details not given. ACT DMD, Ataluren Confirmatory Trial in Duchenne Muscular Dystrophy; BMI, body mass index; DFZ, deflazacort; DMD, Duchenne muscular dystrophy; LoA, loss of ambulation; PRED, prednisone/prednisolone; TEAE, treatment-emergent adverse event.
Observational studies comparing outcomes with deflazacort and prednisone/prednisolone include two analyses from the CINRG Duchenne Natural History Study. The first was an analysis of data from 340 patients, with average follow-up of 3.8 years [7], and the second was an extension of the same CINRG natural history study that included an additional 100 patients with up to 10 years of follow-up (described earlier in the current review) [27].

In the initial analysis of 340 patients, deflazacort was associated with later LoA than prednisone/prednisolone (HR 0.294 ± 0.053 vs 0.490 ± 0.08; p = 0.003 [7]. The average dose was lower for daily prednisone/prednisolone (0.56 mg/kg/d, 75% of recommended dose) than daily deflazacort (0.75 mg/kg/d, 83% of recommended dose). The most frequently observed TEAEs were weight gain, Cushingoid appearance, growth retardation, behavior changes, low bone density and/or fracture, cataracts, and skin abnormalities. Of these, weight gain was similar with either steroid, but patients receiving deflazacort showed higher incidences of Cushingoid appearance, growth retardation, and cataracts [7].

In the extension study, compared with the prednisone/prednisolone group, patients in the deflazacort group had significantly increased age at loss of supine-to-stand (p = 0.0114), age at LoA (p = 0.0102), and age at loss of hand-to-mouth function (p = 0.0110) [27]. A summary of results on timed function tests and disease milestones can be found in Table 3 [27, 44]. The most common TEAEs seen among patients treated daily with prednisone/prednisolone vs deflazacort (calculated across person-years) were weight gain (14% vs 5%), Cushingoid appearance (9% vs 6%), growth retardation (4% vs 5%) and behavioral changes (6% vs 3%) [27].

Deflazacort (relative to prednisone) use was significantly associated with a longer time to loss of ability to rise from supine in an analysis of data from 316 ambulatory boys from four natural history databases (UZ Leuven, CureDuchenne, iMDEX and ImagingDMD) [45]. The median age of the patients was 7.9 years (range, 4.4–19.4 years); 64% of patients were receiving deflazacort and 36% were receiving prednisone. Overall, 119 boys (38%) lost stand from supine ability over 900 patient-years of follow-up. Baseline rise velocity, better 4-stair climb performance and younger age at baseline were also associated with a longer time to loss of rise from supine ability. A sensitivity analysis incorporating data from placebo arms of clinical trials provided similar results.

A retrospective review of 832 patients with DMD in the UK NorthStar database (2006–2015) focused on fracture morbidity and growth, stratifying outcomes by type of corticosteroid used [24]. The median age at baseline was 6.9 years (interquartile range 4.9–7.2 years) and most boys were ambulant. The median follow-up was 4 years (interquartile range 2.0–6.0). The fracture incidence was 682 per 10,000 person-years (95% CI, 579–798). In total, 564 participants had complete information about glucocorticoid use. The majority of patients received prednisolone, either daily (n = 152) or intermittently (n = 131), with 41 patients receiving daily deflazacort, 13 intermittent deflazacort, 183 a mixed regimen, and 44 patients were glucocorticoid naïve. Fracture incidence was highest in the daily deflazacort group at 1367 per 10,000 person-years, compared with 748 per 10,000 person-years in the daily prednisolone group. For intermittent treatment the incidences were 577 and 512 per 10,000 person-years for deflazacort and prednisolone, respectively. Hazard for first fracture was increased by 3.7-fold (95% CI, 1.5–9.2; p = 0.005) in ambulant patients. Only age was considered in the hazard analysis; ambulatory status, which is a useful bone health indicator [46], was not considered. Ideally, fracture incidence data should be collected prospectively, rather than retrospectively, and fractures should have been radiologically confirmed in the study [46]. A US study using data from the MDSTARnet population-based surveillance system analyzed height, weight and BMI measurements from 324 ambulatory patients aged between 2 and 12 years who were treated with corticosteroids for at least 6 months [23]. Patients treated with corticosteroids were shorter than ambulatory, steroid-naïve males with DMD and it appeared that average height became increasingly arrested as steroid treatment continued. Deflazacort was associated with shorter stature and significantly less weight gain than prednisone. It has been proposed that short stature may confer a biomechanical advantage in the setting of lower extremity weakness, delaying LoA, and may in fact be one of the mechanisms by which corticosteroids extend ambulation in DMD [47, 48]. In a recent retrospective review of 70 patients with DMD, those who lost ambulation at a later age were signifi-
Table 3

Median age of transition to ambulatory and upper limb function milestones

| Milestone                                      | Length of glucocorticoid use | Glucocorticoid used               |
|------------------------------------------------|------------------------------|-----------------------------------|
|                                                | ≥1 year                      | Never or <1 year                  |
| Ambulatory milestones                          |                              | Dexamethasone                     |
| Transition to ≥ 5 s stand from supine          | 10.02*                       | 5.66                              |
|                                                | 11.74*                       | 11.37                             |
| Transition to ≥ 10 s stand from supine         | 11.62*                       | 9.56                              |
|                                                | 13.17†                       | 13.10                             |
| Loss of ability to stand from supine           | 13.40*                       | 10.00                              |
|                                                |                              | 14.00†                            |
| Loss of ability to climb 4 stairs              |                              |                                   |
| Loss of ambulation                             | 13.40*                       | 10.00                              |
|                                                |                              | 14.00†                            |
| Upper limb milestones                          |                              |                                   |
| Loss of full overhead reach                    | 12.40‡                       | 9.56                              |
|                                                |                              | 14.33                             |
| Loss of unweighted hand-to-mouth function      | 20.48¶                       | 15.41                             |
|                                                |                              | 20.48#                            |
| Loss of hand function (ability to pick up small objects) | 31.11*                       | 23.09                             |
|                                                |                              | Insufficient number of transitions|
|                                                |                              | Insufficient number of transitions|

*p < 0.0001 vs <1 month of corticosteroid use. †p = 0.0114 vs prednisone/prednisolone (log-rank values). ‡p = 0.0023 vs <1 month of corticosteroid use. †p = 0.0102 vs prednisone/prednisolone (log-rank values). ‡p = 0.0080 vs <1 month of corticosteroid use. ‡p = 0.0113 vs <1 month of corticosteroid use. ¶p = 0.0110 vs prednisone/prednisolone (log-rank values). Adapted from McKeage 2018 [44]; Kaplan-Meier analyses from McDonald 2018 [27].

There is some evidence that long-term deflazacort increases the likelihood of cataracts. A retrospective review of 596 patients with DMD found that the prevalence of cataracts was 22.4% among the 514 patients receiving corticosteroids [50]. The odds of cataract development were 2.4-fold higher among patients taking deflazacort than those receiving prednisone (95% CI, 1.3–4.5; p = 0.004). Seven patients underwent cataract surgery, all of whom were receiving deflazacort. A combination of reduced lipid solubility and presumed increased availability to aqueous compartments and decreased dose reductions could explain the increased risk of cataracts with deflazacort.

There is also some evidence that deflazacort and prednisone/prednisolone may have different impacts on behavior. A questionnaire-based study of 67 ambulant patients and their parents indicated that patients taking deflazacort exhibited more withdrawn behavior than those taking prednisone/prednisolone, whereas patients taking prednisone/prednisolone exhibited more aggressive behavior than those taking deflazacort [18].

The varying doses of corticosteroids reported in real-world, prospective natural history studies complicate interpretations of safety and efficacy. However, the DMD care considerations do not mandate that doses of deflazacort and prednisone need to have weight-based adjustments over time [37]. The real-world evidence from such prospective natural history studies does provide insights into how these corticosteroids compare with real clinical practice. If one corticosteroid regimen is typically adjusted downward due to side effects, there is still value in considering such real-world data obtained in large cohorts over multiple years.

**Post-hoc analyses in placebo arms of industry-sponsored clinical trials**

The placebo arms of clinical trials in patients with DMD, in which participants continue their pre-trial glucocorticoid treatment, can potentially offer an additional, low-level evidence insight into use of deflazacort vs prednisone/prednisolone. Limited conclusions can be drawn from these analyses because they were not originally designed to compare these treatments and hence bias is introduced because of the lack of randomization to glucocorticoid treatment. However, the increased age ranges of patients included in these trials gives insights into experiences with more prolonged dosing beyond the ages of 7 to 10 years.

A non-prespecified post-hoc analysis of the placebo arm of the Ataluren Confirmatory Trial in DMD (ACT DMD; ClinicalTrials.gov Identifier: NCT01826487) included patients aged 7 to 16 years, 53 of whom were treated with deflazacort and 61 of whom were treated with prednisone/prednisolone.
Despite patients not being randomized to corticosteroid treatment, the characteristics of the two groups were well balanced and not significantly different at baseline. Mean age was 9.2 (SD 1.7) and 8.8 (SD 1.6) years, and mean weight 30.9 kg (SD 11.9 kg) and 30.5 kg (SD 9.2 kg) in the deflazacort and prednisone/prednisolone groups, respectively. Most patients had received corticosteroid therapy for at least 12 months before entering the study (86.8% of patients receiving deflazacort and 82.0% of patients receiving prednisone/prednisolone). At 48 weeks, mean changes in 6-minute walking distance (6MWD) were –39.0 m for deflazacort (95% CI, –68.85, –9.17) and –70.6 m for prednisone/prednisolone (95% CI, –97.16, –44.02). Mean changes in time to perform the 4-stair climb were 3.79 s for deflazacort (95% CI, 1.54–6.03) and 6.67 s for prednisone/prednisolone (95% CI, 4.69–8.64) [51]. Although the post hoc nature of this analysis makes its findings inconclusive, it does suggest greater preservation of 6MWD and 4-stair climb performance with deflazacort compared with prednisone/prednisolone. Deflazacort was associated with a slightly lower mean change in height over 48 weeks than treatment with prednisone/prednisolone (total score, 1.2-point difference). There was a slightly lower mean increase in weight in the deflazacort vs prednisone/prednisolone (n = 70; mean daily doses of 0.785 mg/kg and 0.695 mg/kg in the Phase IIb and ACT-DMD studies, respectively [87.2% and 77.2% of the recommended starting dose]) or prednisone/prednisolone (n = 84; mean daily doses of 0.684 mg/kg and 0.515 mg/kg, respectively [91.2% and 68.7% of the recommended starting dose]) for 48 weeks. The analysis found that treatment differences favored deflazacort vs prednisone/prednisolone for the 6MWD (LS mean difference [95% CI], 39.5 m [13.8–65.3]; p = 0.0026), 4-stair climb (LS mean difference [95% CI], 2.7 s [0.7–4.7]; p = 0.0079), and 4-stair descend (LS mean difference [95% CI], 2.4 s [0.3–4.5]; p = 0.0244). Like the first post-hoc meta-analysis, there was no significant difference in the performance of the 10 m walk/run test between the glucocorticoid groups.

Finally, a recent post-hoc analysis of data from the ACT DMD trial evaluated patients' cumulative counts of failures to perform each NSAA item, measured as a transition from 2/1 (able/impaired) to 0 (unable), over 48 weeks [54]. Curves depicting the group-wise mean cumulative failure count for patients of the placebo control arm who received deflazacort or prednisone/prednisolone revealed a steeper curve for prednisone/prednisolone than for deflazacort. The mean cumulative failure rate reduced by 28% in deflazacort-treated versus prednisone/prednisolone-treated patients over the study duration (rate ratio, 0.72; 95% CI, 0.53–0.96; p = 0.028), reflecting a sustainable treatment effect of deflazacort.

**Limitations to studies comparing deflazacort with prednisone/prednisolone**

Clinical studies of boys with DMD present many challenges. It is difficult to find well-matched cohorts of patients owing to differences in the age of symptom onset and the broad spectrum of disease severity, which may be due, at least in part, to different mutations within the dystrophin gene [55]. Owing to limitations in our understanding of DMD, the most appropriate methods to evaluate skeletal muscle strength and function are still being elucidated [56, 57]. Furthermore, the use of BMI, to indicate if a person has a healthy weight, is of
trials. It is also difficult to match cohorts of patients because boys with significant developmental delays are often excluded from trials owing to unreliable test results. There is considerable variability in individuals’ response to glucocorticoids, which is complicated by the different dosing for deflazacort and prednisone/prednisolone and dose adjustments. Given all these variables and challenges, it is difficult to get perfectly matched cohorts for randomized and controlled trials.

Most of the data from the post-hoc analyses in placebo arms of industry-sponsored clinical trials were on individuals with DMD due to a premature stop codon. These results may not apply to all individuals with DMD due to exon deletions, duplications or missense mutations.

DISCUSSION

Glucocorticoids are the standard of care for DMD, although they are ultimately non-curative. Their long-term use improves skeletal muscle strength; preserves upper extremity, cardiac, and pulmonary function; delays LoA and scoliosis; and maintains quality of life.

Compared with prednisone/prednisolone, deflazacort has lower lipid solubility, causes less sodium retention, and has fewer effects on glucose metabolism. The body of evidence from randomized clinical trials, prospective studies, meta-analyses, and post-hoc analyses suggests that deflazacort may be more effective than prednisone/prednisolone at delaying disease progression in DMD, at least in terms of muscle strength, motor function, timed motor function, and time-to-LoA. Of note, observational and post hoc studies have shown deflazacort to be associated with delayed loss of supine-to-stand ability, which is an important early disease milestone to assess that predicts subsequent loss of ambulation. Deflazacort is associated with a lower potential for weight gain and difficult behavior. Bone health, cataracts and growth parameters appear worse with deflazacort than prednisone/prednisolone. In addition to their relative efficacy and safety profiles, medication costs will inevitably be a major factor in treatment choice decisions between the two drugs; deflazacort, in the US at least, is considerably more expensive than prednisone.

The choice of corticosteroid extends beyond the clinical data as healthcare costs are also important. A detailed discussion surrounding costs is out of the scope of this review, but with governments and other payers increasingly struggling to cover the costs of expensive new treatments [59], this subject is important to acknowledge. Deflazacort is markedly more expensive than prednisone in the US [60], but it is also associated with pharmacological and clinical benefits, as described above. Before initiating glucocorticoid treatment, it is important for physicians, patients, and parents to discuss benefits and risks of various regimens, including costs [61], but ultimately the choice of treatment will be decided by third party payers in many cases. There are initiatives in place to help make therapies for DMD more affordable and accessible, such as Project Hercules [62], a UK-based consortium of pharmaceutical companies, charities, academics, patient organizations, experts and clinicians – stakeholders whose interests are often difficult to align. Deflazacort has a manufacturer-supported patient assistance and access program [63].

Because deflazacort was only recently approved in the US, real-world comparative data for deflazacort versus prednisone/prednisolone in the US are still emerging [44], but one observation from the deflazacort Early Access Program is that when lower doses than recommended were given, the variance between recommended dose and administered dose increased as patient weight increased [64]. Most clinicians do not appear to be making weight-based increases in doses of either prednisone or deflazacort. This may have implications for long-term outcomes, side effects, and optimal management. Optimizing dosing regimens is the goal of the ongoing, phase 3 Finding the Optimum Regimen for DMD (FOR-DMD; NCT01603407) trial [65]. This trial is comparing three regimens: daily prednisone/prednisolone at 0.75 mg/kg/d; intermittent prednisone/prednisolone at 0.75 mg/kg/d for 10 days, then 10 days of drug holiday; or daily deflazacort at 0.9 mg/kg/d [66]. The hypothesis is that daily treatment with either glucocorticoid will be more beneficial than intermittent dosing. A secondary outcome will be to compare AE profiles [65, 66]. The trial focuses on a population of patients with a narrow age range of 4 to 7 years with a 36-month follow-up, so its results cannot be extrapolated to patients older than 10 years old, who are in the decline phase of the disease. Thus, the FOR-DMD trial will not address the safety and efficacy profiles of deflazacort and prednisone/prednisolone in older
patients where there may be different bioavailability of the drugs to muscle fibers due to fatty replacement of musculature with increasing age.

It should also be noted that alternative options to deflazacort and prednisone/prednisolone for the management of DMD are now reaching the market or are progressing through clinical development. New drugs targeting NFXB include the dissociative steroid vamorolone [67, 68], while other therapies aim to restore the function or expression of dystrophin, including eteplirsen, casimersen, golodirsen and viltolarsen, which are approved exon skipping drugs for use in the US, and ataluren, a premature stop codon read-through medication approved for use in the EU and other countries [68]. These therapies may in future prove to be useful alternatives to deflazacort and prednisone/prednisolone.

ACKNOWLEDGMENTS

Medical writing and editorial support were provided by Rosalyn Blumenthal, PhD, Beverly Barton, PhD, and Brandy Weidow, MS, ELS of Brightest-Solutions, LLC, and Richard Claes, PhD and Tim Ellison, PhD, of PharmaGenesis London, London, UK, and were funded by PTC Therapeutics, Inc.

CONFLICT OF INTEREST

W. Douglas Biggar, MD has served as a consultant for PTC Therapeutics and Marathon.

Andrew Skalsky, MD has no conflicts of interest to report.

Craig M. McDonald, MD has served as a consultant for clinical trials for PTC Therapeutics, and outside the submitted work with Astellas Pharma, Avidity Biosciences, Capricor Therapeutics, Catabasis Pharmaceuticals, Edgewise Therapeutics, Entrada Therapeutics, Epirio Bio (formerly Cardero Therapeutics), FibroGen, Italfarmaco, Pfizer, PTC Therapeutics, Roche, Santhera Pharmaceuticals and Sarepta Therapeutics. He has received research support for clinical trials from Capricor Therapeutics, Catabasis Pharmaceuticals, Italfarmaco, Pfizer, PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics. He has served on external advisory boards related to Duchenne muscular dystrophy for PTC Therapeutics, Edgewise Therapeutics, Eli Lilly, Sarepta Therapeutics, Santhera Pharmaceuticals, and Capricor Therapeutics.

The authors received no compensation for writing this article.

REFERENCES

[1] Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71(3):304-13.
[2] Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet. 2013;21(10):1049-53.
[3] Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review. Orphanet J Rare Dis. 2017;12(1):79.
[4] Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurmti DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature. 1986;323(6089):646-50.
[5] Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. J Cell Biol. 1995;128(3):355-61.
[6] Darras BT, Miller DT, Urion DK. Dystrophinopathies. 2014. In: GeneReviews® [Internet]. Seattle, WA: University of Washington. Available from: https://www.ncbi.nlm.nih.gov/books/NBK11119/.
[7] Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85(12):1048-55.
[8] Drugs.com. PTC Therapeutics receives FDA approval for the expansion of the Emflaza (deflazacort) labeling to include patients 2-5 years of age. June 7, 2019. Available from: https://www.drugs.com/newdrugs/ptc-therapeutics-receives-fda-approval-expansion-emflaza-deflazacort-labeling-include-patients-2-5-4989.html (Accessed 21 January 2021).
[9] David FS, Dixit R. How to prevent the next Marathon Pharmaceuticals. F1000Res. 2018;7:74.
[10] Parente L. Deflazacort: Therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1.
[11] Jensen L, Petersson SJ, Illum NO, Laugaard-Jacobsen HC, Thelle T, Jørgensen LH, et al. Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy. J Musculoskelet Neuronal Interact. 2017;17(2):8-18.
[12] Lit L, Sharp FR, Apperson M, Liu DZ, Walker WL, Liao I, et al. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy. Pharmacogenomics J. 2009;9(6):411-8.
[13] Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317-33.
[14] Quinkler M, Oelkers W, Diedrich S. Clinical implications of glucocorticoid metabolism by 11beta-hydroxysteroid dehydrogenases in target tissues. Eur J Endocrinol. 2001;144(2):87-97.
[15] Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokin. 2005;44(1):61-98.
[16] Nayak S, Achariya B. Deflazacort versus other glucocorticoids: A comparison. Indian J Dermatol. 2008;53(4):167-70.
[17] Assandri A, Buniva G, Martinelli E, Perazzi A, Zerilli L. Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man. Adv Exp Med Biol. 1984;171:9-23.
[18] Sienko S, Buckon C, Fowler E, Bagley A, Staudt L, Sison-Williamson M, et al. Prednisone and deflazacort in Duchenne muscular dystrophy: Do they play a different role in child behavior and perceived quality of life? PLoS Currents. 2016;8:ecurrents.md.7628d9c014bfa29f8215acd19723bbaa.
[19] Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromusc Dis. 2006;16(4):249-55.
[20] Kwon S, Herrmayer KL, Herrmayer K. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013;345(4):274-7.
[21] Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in non-diabetic patients: A meta-analysis. Ann Nutr Metab. 2014;65(4):324-32.
[22] Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AF, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: A comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151(3):397-406.
[23] Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K, et al. Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy. J Pediatr. 2016;173:207-13 e3.
[24] Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, et al. Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: Results from the UK NorthStar database. JAMA Neurol. 2019;76(6):701-9.
[25] Trucco F, Månsson E, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-67.
[26] Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, the MDS. Corticosteroid treatments in males with Duchenne muscular dystrophy: Treatment duration and time to loss of ambulation. Journal of Child Neurology. 2015;30(10):1275-80.
[27] Trouffo D, Domingos JP, Tay CG, Ridout D, Maresh K, Munot F, et al. Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne Muscular Dystrophy: A single-site retrospective longitudinal study. Chest. 2020;158(4):1606-16.
[28] Quattrocelli M, Zelikovich AS, Jiang Z, Peck CB, Dembrenur AR, Kunzt NL, et al. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. JCI Insight. 2019;4(24).
[29] Zelikovich AS, Quattrocelli M, McNally EM, Kunzt NL. Improved metabolic and bone health in boys with Duchenne muscular dystrophy treated with high dose pulse weekend corticosteroids compared to daily dosing. Neurology. 2020;94 (15 Supplement).
[30] Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-67.
[31] Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, the MDS. Corticosteroid treatments in males with Duchenne muscular dystrophy: Do they play a different role in child behavior and perceived quality of life? PLoS Currents. 2016;8:ecurrents.md.7628d9c014bfa29f8215acd19723bbaa.
[32] Hendriksen RGF, Lionarons JM, Hendriksen JGM, Vles JSH, McAdam LC, Biggar WD. Development of a new self-reporting instrument measuring benefits and side effects of corticosteroids in Duchenne muscular dystrophy: Report from a pilot study. J Neuromuscul Dis. 2017;4(3):217-36.
[33] Karimzadeh P, Ghazavi A. Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iran J Child Neurol. 2012;6(1):5-12.
[34] Biere Y, Pfeiffer AF, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: A comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151(3):397-406.
[35] Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, the MDS. Corticosteroid treatments in males with Duchenne muscular dystrophy: Treatment duration and time to loss of ambulation. Journal of Child Neurology. 2015;30(10):1275-80.
[36] Trouffo D, Domingos JP, Tay CG, Ridout D, Maresh K, Munot F, et al. Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne Muscular Dystrophy: A single-site retrospective longitudinal study. Chest. 2020;158(4):1606-16.
[37] Quattrocelli M, Zelikovich AS, Jiang Z, Peck CB, Dembrenur AR, Kunzt NL, et al. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. JCI Insight. 2019;4(24).
[38] Zelikovich AS, Quattrocelli M, McNally EM, Kunzt NL. Improved metabolic and bone health in boys with Duchenne muscular dystrophy treated with high dose pulse weekend corticosteroids compared to daily dosing. Neurology. 2020;94 (15 Supplement).
[39] Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-67.
[40] Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, the MDS. Corticosteroid treatments in males with Duchenne muscular dystrophy: Do they play a different role in child behavior and perceived quality of life? PLoS Currents. 2016;8:ecurrents.md.7628d9c014bfa29f8215acd19723bbaa.
ability to rise from supine in Duchenne muscular dystrophy (DMD). Neuromuscul Disord. 2020;30(Supplement 1):S63-4.

[46] Mayo AL, Craven BC, McAdam LC, Biggar WD. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy. Neuromuscular Disord. 2012;22(12):1040-5.

[47] Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138(1):45-50.

[48] Bodor M, McDonald CM. Why short stature is beneficial in Duchenne muscular dystrophy. Muscle Nerve. 2013;48(3):336-42.

[49] Labove L, Jaworski M, Nguyen C-TE. Duchenne muscular dystrophy: Do boys with a shorter stature maintain ambulation longer? J Neuromusc Dis. 2018;5(Supplement 1):S142-83.

[50] Rice ML, Wong B, Horn PS, Yang MB. Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients. J AAPOS. 2018;22(3):192-6.

[51] Shieh PB, McIntosh J, Jin F, Souza M, Elfring G, Narayanan S, et al. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Muscle Nerve. 2018;58(5):639-45.

[52] McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, et al. Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2020;61(1):26-35.

[53] Shieh PB, Elfring G, Trifillis P, Santos C, Peltz SW, Parsons JA, et al. Meta-analyses of deflazacort versus prednisolone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. J Comp Elf Res. 2021;10(18):1337-47.

[54] McDonald CM, Wei LJ, Flanigan KM, Elfring G, Trifillis P, Muntoni F, et al. Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment. Muscle Nerve. 2021.

[55] Sun C, Shen L, Zhang Z, Xie X. Therapeutic strategies for Duchenne muscular dystrophy: An update. Genes (Basel). 2020;11(8).

[56] Killian M, Buchowski MS, Donnelly T, Burnette WB, Markham LW, Slaughter JC, et al. Beyond ambulation: Measuring physical activity in youth with Duchenne muscular dystrophy. Neuromuscul Disord. 2020;30(4):277-82.

[57] Shieh PB. Duchenne muscular dystrophy: Clinical trials and emerging tribulations. Curr Opin Neurol. 2015;28(3):542-6.